share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K:外國發行人報告
美股SEC公告 ·  09/16 06:21
Moomoo AI 已提取核心訊息
NeuroSense Therapeutics Ltd., a foreign private issuer, has filed a report with the United States Securities and Exchange Commission (SEC) for the month of September 2024. The report, submitted on Form 6-K, indicates that NeuroSense Therapeutics has begun the process of complying with the Health Insurance Portability and Accountability Act (HIPAA) regulations. This initiative is part of the company's regulatory obligations in the United States. The filing, dated September 16, 2024, was signed by Alon Ben-Noon, an authorized representative of NeuroSense Therapeutics.
NeuroSense Therapeutics Ltd., a foreign private issuer, has filed a report with the United States Securities and Exchange Commission (SEC) for the month of September 2024. The report, submitted on Form 6-K, indicates that NeuroSense Therapeutics has begun the process of complying with the Health Insurance Portability and Accountability Act (HIPAA) regulations. This initiative is part of the company's regulatory obligations in the United States. The filing, dated September 16, 2024, was signed by Alon Ben-Noon, an authorized representative of NeuroSense Therapeutics.
NeuroSense Therapeutics Ltd.,一家外國私人發行人,已向美國證券交易委員會(SEC)提交了2024年9月的報告。該報告是以6-k表格提交的,表明NeuroSense Therapeutics已經開始遵守《健康保險移植與責任法案》(HIPAA)的法規。這一舉措是公司在美國的監管義務的一部分。文件日期爲2024年9月16日,由NeuroSense Therapeutics的授權代表Alon Ben-Noon簽署。
NeuroSense Therapeutics Ltd.,一家外國私人發行人,已向美國證券交易委員會(SEC)提交了2024年9月的報告。該報告是以6-k表格提交的,表明NeuroSense Therapeutics已經開始遵守《健康保險移植與責任法案》(HIPAA)的法規。這一舉措是公司在美國的監管義務的一部分。文件日期爲2024年9月16日,由NeuroSense Therapeutics的授權代表Alon Ben-Noon簽署。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息